Product Description
The research-grade biosimilar is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of IL-23 but does not bind to IL12. IL-23 is expressed and secreted by dendritic cells and macrophages. It belongs to the family of IL-12 cytokines and has two subunits: p40 that is shared with IL-12 and p19 that is unique for IL-23. IL-23 plays a critical role in maintaining and expanding Th17 cells. It also stimulates multiple innate immune cells such as myeloid cells and NK cells to produce proinflammatory cytokines that play an important role in the pathogenesis of inflammatory diseases such as Ulcerative Colitis (UC). By binding to the p19 subunit of IL-23, the antibody inhibits the release of proinflammatory cytokines and reduces the inflammatory response. The original drug is currently undergoing clinical trials to treat moderate-to-severe UC, psoriasis, and Crohns disease
Biovision | A2174 | Anti-IL23? (Mirikizumab), Humanized Antibody DataSheet
Antibody Target: IL23?
Target Alternative Name: LY-3074828, LY3074828, P19, SGRF, IL-23, IL23A, IL23P19
Tag Line: The biosimilar is a humanized monoclonal antibody that targets IL-23 and inhibits the pathogenesis of chronic inflammatory diseases such as psoriasis
Category: Biosimilars
Host: Recombinant
Isotype: IgG4, kappa
Species Reactivities: Human
Immunogen Sequence: Human IL23?
Accession #: DB14910
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE